Czech and Slovak Ophthalmology 19 Original article Two-year follow-up Results of Patients with Macular Edema due to Retinal Vein Occlusion Treated with Ranibizumab Hladíková Zuzana Klofáčová Eva Kalvodová Bohdana 12 7 2017 2 1

Purpose: To evaluate 2-year follow-up results of patients with macular oedema (ME) caused by central (CRVO) and branch (BRVO) retinal vein occlusion treated with intravitreal ranibizumab at the Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic. Methods: Retrospective study. Results: The 2-year follow-up was completed by 18 patients with ME caused by CRVO and 16 patients with ME caused by BRVO. In CRVO group mean age at diagnosis was 63 years, mean interval from diagnosis to the beginning of treatment was 3,6 months. During the first year of treatment the mean improvement of best corrected visual acuity (BCVA) was 17,4 letters of Early Treatment Diabetic Retinopathy Study (ETDRS) optotype, during the second year +2,4 letters. Mean number of injections was 6,8 in the first and 3,6 in the second year of treatment, mean total of 10,2 injections. In BRVO group the mean age at diagnosis was 68 years, mean interval from diagnosis to the beginning of treatment 6 month, mean gain in BCVA was +18,7 letters in the first and +1 letters in the second year of treatment, mean number of injections was 7 and 3,2 respectively, mean total of 9,6 injections. In both groups neither ocular nor systemic serious adverse effects were noted. Conclusion: According to our results intravitreal ranibizumab is a safe and effective treatment for ME caused by retinal vein occlusion. Our results in BRVO group were in accordance with published international studies – BRAVO (BRVO) +18,3 letters, HORIZON -0,7 and even slightly better in CRVO group - CRUISE (CRVO) +13,9 letters, HORIZON study -4,1 letters

 macular oedema ranibizumab retinal vein occlusion central retinal vein occlusion branch retinal vein occlusion 2-year follow-up References Bowling, B.: Kanski´s Clinical Ophthalmology: A Systemic Approach, Eighth edition, Edinburgh, Elsevier, 2016, p. 539–44. Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B. et al.: Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. Ophthalmology, 118, 2011: 1594–1602. Campochiaro, P.A., Brown, D.M., Awh C.C. et al.: Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve -Month Outcomes of a Phase III Study. Ophthalmology, 118, 2011: 2041–49. Campochiaro, P.A, Sophie, R., Pearlman, J. et al.: Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab The RETAIN Study. Ophthalmology, 121, 2014: 209– 19. al.: Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion: Two-Year Results from the COPERNICUS Study. Ophthalmology, 121, 2014: 1414–1420. Clark, W.L., Boyer, D.S., Heier, J.S. et al.: Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion 52-Week Results of the VIBRANT Study. Ophthalmology, 123, 2016: 330– 36. Dodson, P.M., Galton, D.J., Hamilton, A.M. et al.: Retinal vein occlusion and the prevalence of lipoprotein abnormalities. Br J Ophthalmol, 66, 1982: 161– Haller, J.A., Bandello, F., Belfort, R. Jr. et al.: Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion Twelve-Month Study Results. Ophthalmology, 118, 2011: 2453–2460. Heier, J.S., Campochiaro, P.A., Yau, L. et al.: Ranibizumab for Macular Edema Due to Retinal Vein Occlusions Longterm Follow-up in the HORIZON Trial. Ophthalmology, 119, 2012: 802–809. Heier, J.S., Clark, W.L., Boyer, D.S. et http://www.sukl.cz/modules/medication/detail.php?code=0167756&tab=prices Klein, R., Klein, B.E.K., Moss, S.E. et al: The Epidemiology of Retinal Vein Occlusion: The Beaver Dam Eye Study. Tr. Am. Ophth. Soc., 98, 2000: 133–143. Kuchynka, P.: Oční lékařství, Praha, Grada Publishing, 2007, 291 s. Mitchell, P., Smith, W., Chang, A.: Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol, 114, 1996: 1243–1247 Noma, H., Funatsu, H., Mimura, T. et al.: Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal Ogura, Y., Roider, J., Korobelnik, J. F. et al.: Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein occlusion: 18-Month Results of the Phase 3 GALILEO Study. See comment in PubMed Commons below Am J Ophthalmol, 158, 2014: 1032–1038. Ponto, K.A., Elbaz, H., Peto, T. et al.: Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J Thromb Haemost, 13, 2015: 1254–1263. Rogers, S., McIntosh, R. L., Cheung, N. et al.: The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology, 117, 2010: 313–319. 271–282. Řehák, J.: Makulární edém u okluze sítnicové vény. In Ernest, J. et al.: Makulární edémy, Praha, Mladá fronta, 2014, s. 176–199. Řehák J., Rehák, M.: Venózní okluze sítnice, Praha, Grada Publishing, Praha, 2011, s. 51, s. 58. Sivaprasad, S., Amoaku, W. M., Hykin, P. et al.: The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary. Eye, 29, 2015: 1633–1638. Studnička J., Dusová, J., Skoupá, J. et al.: Léčba makulárního edému při okluzi centrální sítnicové žíly Ozurdexem. Čes. a Slov. Oftal, 71, 2015: 199–203. The Branch Vein Occlusion Study Group: Argon Laser Photocoagulation for Macular Edema in Branch Vein Occlusion. Am J Ophthalmol, 98, 1984: vein occlusion. Eur J Ophthalmol, 20, 2010: 402–409. The Central Vein Occlusion Study Group: Natural History and Clinical Management of Central Retinal Vein Occlusion, Arch Ophthalmol, 115, 1997: 486–491. The Central Vein Occlusion Study Group M report: Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology, 102, 1995: 1425–1433. The Central Vein Occlusion Study Group N report: A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology, 102, 1995: 1434–1444. The Eye Disease Case-Control Study Group: Risk Factors for Central Retinal Vein Occlusion. Arch Ophthalmol. 114, 1996: 545–554.